Sven Kili

Dr Sven Kili is Chief Executive Officer at Antion Biosciences, a Multiplex Cell Engineering company developing ‘Smart-Data’ driven in-vivo allogeneic cell therapies for underserved patients suffering from recalcitrant diseases. He was previously the Head of Development for the Cell and Gene Therapy division of GSK Rare Diseases where he led teams developing and commercialising Gene Therapies for a variety of rare genetic disorders including Strimvelis®, the first ex-vivo gene therapy to be approved for children with ADA-SCID; Wiskott – Aldrich syndrome (WAS); Metachromatic Leukodystrophy (MLD) and Beta-Thalassemia. Prior to this, he was Senior Director, Cell Therapy and Regenerative Medicine for Sanofi (Genzyme) Biosurgery where he led the clinical development, approval and commercialisation activities of the first combined ATMP product in the EU for MACI®.